James Falcon
Family Medicine · Rio Grande City, TXNPI 1144480815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 41.0% of the total. 2025 is the largest year on record at $100, 4.6 times the $22 reported in 2023. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 6 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$80
- Lilly USA, LLC$31
- Nevro Corp.$22
- AbbVie$22
- Phadia US Inc.$20
- Dexcom, Inc.$20
Across 14 payments — averaging $50,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$693K
- Genentech, Inc.$18K
What the payments were for
- Food & beverage$195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 1 | $80 |
| Lilly USA, LLC | 1 | $31 |
| Nevro Corp. | 1 | $22 |
| AbbVie | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
How this compares
$195 in reported general payments places this provider in the 35th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $42,476 |
| OzempicSemaglutide | 39 | $36,105 |
| JanuviaSitagliptin Phosphate | 19 | $29,298 |
| LinzessLinaclotide | 29 | $27,874 |
| FarxigaDapagliflozin Propanediol | 22 | $25,203 |
| TrulicityDulaglutide | 25 | $24,536 |
| TradjentaLinagliptin | 17 | $17,163 |
| MyrbetriqMirabegron | 13 | $9,750 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,223 |
| Levemir FlexpenInsulin Detemir | 11 | $1,672 |
| Metoprolol Succinate | 79 | $1,573 |
| Novolog FlexpenInsulin Aspart | 11 | $1,378 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 58 | $1,226 |
| Atorvastatin Calcium | 109 | $1,152 |
| Omeprazole | 52 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $22 | $27,87429 claims |
| Lilly USA, LLCTrulicity | $31 | $24,53625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Rio Grande City
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.